关注新生血管性年龄相关性黄斑变性的创新药物治疗  

Focusing on innovative drug therapy for neovascular age-related macular degeneration

作　　者：卢颖毅[1] 赵晶[1] 戴虹[1] Lu Yingyi;Zhao Jing;Dai Hong(Department of Ophthalmology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]北京医院眼科,国家老年医学中心,中国医学科学院老年医学研究院,北京100730

出　　处：《中华实验眼科杂志》2024年第5期401-407,共7页Chinese Journal Of Experimental Ophthalmology

基　　金：首都卫生发展科研专项(2020-2-4051)。

摘　　要：湿性年龄相关性黄斑变性(nAMD)是老年人致盲的主要原因,抗VEGF是其主要治疗方法。目前,nAMD治疗仍面临诸多不足和挑战,开发新的治疗药物和给药方法是其主要研究的方向。近年来治疗nAMD的药物研发方向呈现多样化,包括开发新靶点/新机制药物及新型给药方式、优化给药剂量和基因疗法等,达到降低治疗频率、延长治疗间隔、提高患者治疗依从性和长期维持或改善视力的目的。眼科临床医师应对新的药物有较为全面的了解,进而发掘出适合不同nAMD亚型患者的优化方案,实现向精准化医疗迈进。Wet age-related macular degeneration(nAMD)is the leading cause of blindness in the elderly,and anti-VEGF is its main treatment method.At present,the treatment of nAMD still faces many shortcomings and challenges,and the development of new therapeutic drugs and delivery methods is the research focus.In recent years,the direction of drug research and development for the treatment of nAMD has shown diversification,including the development of new target/mechanism drugs and new drug delivery methods,optimization of drug dosage and gene therapy,etc.,in order to reduce treatment frequency,prolong treatment interval,improve patient compliance,and maintain or improve vision in the long term.Ophthalmologists should have a comprehensive understanding of new drugs and explore strategies appropriate for patients with different subtypes of nAMD to achieve a move toward precision medicine.

关 键 词：年龄相关性黄斑变性 治疗 抗VEGF 创新药物 

分 类 号：R774.5[医药卫生—眼科]